Silexion Therapeutics Corp: Annual Report Summary for Fiscal Year 2025

Silexion Therapeutics Corp's latest annual report for the fiscal year ended December 31, 2025, reveals key insights into their progress and financial standing. This summary breaks down their business, financial performance, and future outlook in plain language, helping investors understand the company's journey.

Business Overview

Silexion Therapeutics Corp is a clinical-stage biotechnology company dedicated to developing new treatments for KRAS-driven cancers. Imagine KRAS as a faulty cellular switch that can trigger cancer; Silexion aims to deactivate it. The company employs RNA-interference therapeutics—a specialized approach that 'silences' these cancer-causing genes. Their lead product candidate, SIL204, targets locally advanced pancreatic cancer (LAPC), combining local and systemic treatments with standard chemotherapy.

Financial Performance

For the fiscal year ended December 31, 2025, Silexion reported no revenue from product sales, which is typical for a clinical-stage company. The company's net loss widened to $58.5 million in 2025, compared to $32.1 million in 2024. This increase primarily stemmed from heightened research and development activities.

• Research and Development (R&D) expenses surged to $45.2 million (up from $25.8 million in 2024) as Silexion advanced SIL204 through clinical trials.
• General and Administrative (G&A) expenses reached $13.3 million (compared to $6.3 million in 2024), reflecting costs tied to becoming a public company and expanding operations.

To finance these operations, Silexion secured significant capital:

• $35 million from a public offering in January 2025.
• $15 million from a private placement in September 2025.
• $8.2 million through its "At The Market" (ATM) offering, out of $13.17 million available, providing flexible access to capital.

Risk Factors

• Clinical-Stage Company: As a biotechnology company still in clinical trials, Silexion cannot guarantee that its lead product, SIL204, will achieve success, regulatory approval, or generate revenue. This industry carries inherent high risks and potential high rewards.
• High Cash Burn & Capital Needs: The company operates at a significant loss and will require substantial additional funding to complete clinical trials and potentially commercialize products, which could lead to further shareholder dilution.
• Share Dilution: The continuous need to raise capital by issuing new shares (e.g., through ATM offerings and public offerings) reduces the ownership stake of existing shareholders over time.
• Regulatory Approval Uncertainty: Even with positive clinical data, regulatory approvals from the FDA or other bodies are not guaranteed, yet they are essential for market entry.
• Negative Perception of Reverse Splits: Investors often view reverse stock splits negatively, as these actions, while sometimes necessary, frequently follow periods of low stock prices.
• Intense Competition: The oncology market, particularly for KRAS-driven cancers, is highly competitive, featuring many established pharmaceutical companies and emerging biotechs.
• Smaller Company Status: As a "non-accelerated filer," "smaller reporting company," and "emerging growth company," Silexion benefits from fewer reporting requirements but also has a shorter operating history, which can contribute to higher stock price volatility.

Management's Discussion and Analysis (MD&A) Highlights

The fiscal year 2025 marked a period of significant foundational and clinical progress for Silexion.

• Foundational Milestones: The company officially formed through a business combination on August 15, 2024, merging Silexion Therapeutics Ltd. with Moringa Acquisition Corp. This led to the company's renaming to Silexion Therapeutics Corp and its shares beginning to trade on the Nasdaq stock market (first Global Market, then Capital Market) under symbols "SLXN" (shares) and "SLXNW" (warrants). This transition to a publicly traded entity was a major strategic move, providing access to broader capital markets.
• Clinical Progress: As a clinical-stage company, Silexion's performance centers on advancing its drug candidates. In early 2025, SIL204 successfully completed its Phase 1 dose-escalation study, demonstrating a favorable safety profile and preliminary anti-tumor activity. Following this, the company initiated a Phase 1/2 expansion cohort in mid-2025, focusing on patients with locally advanced pancreatic cancer. This marked crucial progress for their lead program.

Key Achievements:

• Successful Business Combination & Nasdaq Listing: The August 2024 merger and subsequent Nasdaq listing established a crucial foundation, granting access to public investors and enhancing visibility.
• Significant Funding Secured: Silexion successfully raised approximately $58.2 million through various offerings and ATM sales, vital for funding its expensive research.
• Advancement of SIL204: Completing the Phase 1 study and initiating the Phase 1/2 expansion cohort for SIL204 represented significant scientific and clinical milestones.

Challenges and Notable Events:

• Reverse Stock Splits & Share Dilution: Silexion executed two significant reverse stock splits: 1-for-9 in November 2024 and 1-for-15 in July 2025. These actions, often implemented to boost share price and maintain Nasdaq listing requirements, substantially consolidated existing shares. For example, an investor holding 1,350 shares before the November 2024 split would have 150 shares afterward. After the July 2025 split, those 150 shares would become just 10 shares. Despite these consolidations, the total shares outstanding increased from approximately 0.54 million (post-July 2025 split, based on pre-split non-affiliate holdings) to 3.33 million by March 10, 2026. This indicates substantial new share issuance, leading to significant dilution for existing shareholders.
• Increasing Cash Burn: As clinical trials progress, R&D expenses are rising, resulting in a wider net loss and an accelerated cash burn rate.

Leadership and Strategic Changes: The August 2024 business combination was the most significant change in leadership and strategy, effectively creating the current Silexion Therapeutics Corp. This involved a major restructuring, a name change, and a transition to Nasdaq listing, strategically positioning the company to accelerate drug development as a public entity. Additionally, Silexion appointed Dr. Elena Petrova as Chief Medical Officer in June 2025, bringing extensive experience in oncology clinical development and signaling a strategic focus on accelerating clinical programs.

Industry and Regulatory Landscape: Silexion operates within the highly regulated and competitive biotechnology sector, specifically oncology. The oncology market increasingly favors targeted therapies and precision medicine, aligning well with Silexion's focus on KRAS-driven cancers. Regulatory bodies like the FDA are increasingly open to expedited pathways for therapies addressing high unmet medical needs, which could potentially benefit SIL204 if its clinical data proves compelling. However, the regulatory landscape for novel RNA-interference therapies continues to evolve, requiring careful navigation. The success of Silexion's RNA-interference therapeutics hinges on navigating complex clinical trials and securing regulatory approvals.

Financial Health

As of December 31, 2025, Silexion held $38.7 million in cash and cash equivalents. Based on its current spending rate (burn rate), management estimates this cash can fund operations into the third quarter of 2026. Consequently, Silexion will likely need to raise additional capital within the next 6-9 months to sustain its research and development efforts.

The company also has a promissory note with a sponsor, with $1.633 million outstanding at year-end 2025. This note carries an 8% annual interest rate and matures in August 2027.

Future Outlook

Looking ahead, Silexion's immediate future hinges on the progress of SIL204. Key milestones for 2026 include:

• Completing enrollment for the Phase 1/2 expansion cohort.
• Presenting initial clinical data from this cohort in late 2026.

Silexion also plans to explore potential strategic partnerships to support further development and commercialization, recognizing the substantial capital required for late-stage trials. The company's long-term success will depend critically on its ability to secure additional funding and achieve positive clinical trial results.

Competitive Position

Silexion is establishing a niche within the oncology (cancer treatment) sector, specifically targeting KRAS-driven cancers with RNA-interference technology. This area presents significant challenges but also holds immense potential, as KRAS is a common cancer driver historically difficult to treat. Their lead candidate, SIL204, addresses pancreatic cancer—a particularly aggressive and hard-to-treat malignancy—underscoring Silexion's focus on significant unmet medical needs. Although the KRAS-driven cancer space is highly competitive, with numerous established pharmaceutical companies and emerging biotechs exploring various approaches, Silexion's RNA-interference technology offers a distinct mechanism of action.